Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
50
days
First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial
Authors
Yun Fan; Yanqiu Zhao; Dingzhi Huang; Jun Zhao; Tai Qin; Wanyu He; Chenqi Chen; Pu Sun; Kirsha Naicker; Yong SongShow moreShow less
Affiliations
Department of Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou, China; Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China; Department of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department I of Thoracic Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China; Clinical Development–Solid Tumors, BeOne Medicines, Ltd., Beijing, China; Statistics, BeOne Medicines, Ltd., New York, New York; Clinical Biomarkers, BeOne Medicines, Ltd., Beijing, China; Clinical Development–Solid Tumors, BeOne Medicines, Ltd., London, United Kingdom; Department of Respiratory and Critical Care Medicine, Jinling Hospital, Nanjing Medical University, Nanjing, ChinaShow moreShow less
245
days
Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLC
Authors
Santiago Ponce; Miguel Ruiz-Torres; Alejandro Falcón; Gregory M. Cote; Reyes Bernabé; Jessica J. Lin; Juan Manuel Coya; Marta Jiménez-Muñoz; Pablo Fernández-Puyuelo; Amparo Sánchez; Jon Zugazagoitia; Alvaro Ucero; Javier Baena; Helena Bote de Cabo; Mercedes Herrera; Javier Torres-Jiménez; Maria Zurera; Carmen Kahatt; Jose Antonio Lopez-Vilariño; Sara Martinez; Mariano Siguero; Marcos Malumbres; Irene Ferrer; Luis Paz-AresShow moreShow less
Affiliations
Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; Centro Nacional de Investigaciones Oncológicas (CNIO)-Hospital 12 de Octubre (H12O) Lung Cancer Clinical Cancer Research Unit, Instituto de Investigación Biomédica i+12 and CNIO, Madrid, Spain; Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; Massachusetts General Hospital, Boston, Massachusetts; Physiology and Medicine Departments, Universidad Complutense, Madrid, Spain; Oncology Clinical Development, Pharma Mar, Colmenar Viejo, Madrid, Spain; Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, SpainShow moreShow less
99
days
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort
Authors
Oliver Illini; Anna-Carina Hund; Hans-Georg Kopp; Mor Moskovitz; Giannis Mountzios; Wolfgang M. Brueckl; Martin Früh; Marie-Elisabeth Leßmann; Petros Christopoulos; Albrecht Stenzinger; Michael Thomas; Roni Gillis; Nir Peled; Fabian Acker; Alfredo Addeo; Andriani Charpidou; Christian Grohé; Horst-Dieter Hummel; Laetitia Mauti; Sacha I. Rothschild; Sabine Schmid; Christian Schumann; Damien Urban; Robert Wurm; Simon Ekman; Marcus Skribek; Franziska Glanemann; Marcel Wiesweg; Christoph Jakob Ackermann; Sofia Agelaki; Petra Hoffknecht; Marko Jakopović; Jens Kern; David König; Katharina Kostenzer; Cornelia Kropf-Sanchen; Eckart Laack; David Lang; Laurenz Nagl; Georg Pall; Martin Reck; Waleed Kian; Anna T. Allemann; Jürgen Alt; David Araújo; Hanibal Bohnenberger; Alexandros Bokas; Hannah Fabikan; Krainer-Jacobs Julie; Christoph Weinlinger; Adrianus Johannes de Langen; Evangelos Georgios Fergadis; Rieke Fischer; Elena Fountzilas; Patrizia Froesch; Nikolaj Frost; Frank Griesinger; Franziska Jordan; Charisios Karanikiotis; Barbara Kiesewetter; Ippokratis Korantzis; Andrea Lopes Machado; Panagiota Economopoulou; Arnold Pilz; Patrick Reimann; Achim Rittmeyer; Akram Saad; Konstantinos Samitas; Karsten Schulmann; Riyaz Shah; Jan Alexander Stratmann; Hossein Taghizadeh; Kai Tammoscheit; Amanda Tufman; Jan-Phillip Weber; Ewald Wöll; Arschang Valipour; Tobias R. Overbeck; Maximilian J. HochmairShow moreShow less
Affiliations
Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria; Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria; Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany; National Network Genomic Medicine, Cologne, Germany; Department of Hematology, Oncology, and Palliative Care, Robert Bosch Center for Tumor Diseases, Stuttgart, Germany; Davidoff Cancer Center, Beilinson MC, Petah Tikva, Israel; 4th Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece; Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuernberg, Nuremberg, Germany; Department of Oncology and Hematology, Cantonal Hospital of St. Gallen, St. Gallen, Switzerland; Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland; Department of Medicine I, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany; Institute for Pathology, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany; Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Germany; Department of Translational Pulmonology, Heidelberg University Hospital, Heidelberg, Germany; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel; Goethe University Frankfurt, University Hospital, Department of Medicine 2, Hematology and Oncology, Frankfurt, Germany; Oncology Department, University Hospital Geneva, Geneva, Switzerland; Oncology Unit, 3rd Department of Internal Medicine and Laboratory Medical School, National and Kapodistrian University of Athens, Sotiria General Hospital, Athens, Greece; Klinik für Pneumologie, Evangelische Lungenklinik, Berlin, Germany; Translational Oncology/Early Clinical Trial Unit (ECTU), Bavarian Cancer Research Center, National Center for Tumor Diseases, Comprehensive Cancer Center Mainfranken and University Hospital Würzburg, Würzburg, Germany; Medizinische Onkologie, Kantonsspital Winterthur, Winterthur, Switzerland; Department of Internal Medicine, Center of Oncology & Hematology, Cantonal Hospital Baden, Baden, Switzerland and University of Basel, Medical Faculty, Basel, Switzerland; Respiratory Critical Care, Allgäu Clinics, Kempten and Immenstadt, Kempten, Germany; Institute of Oncology, Sheba Medical Center, Tel Hashomer, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria; Department of Thoracic Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Department of Oncology and Haematologie Thun-Spiez-Berner-Oberland, Thun, Switzerland; Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece; Department of Thoracic Oncology, Niels-Stensen-Kliniken, Franziskus-Hospital Harderberg, Georgsmarienhütte, Germany; Department for Respiratory Diseases Jordanovac, University Hospital Centre Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia; KWM-Standort Missioklinik, Würzburg, Germany; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland; Department of Pneumology, LKH Hochzirl-Natters, Tirol Kliniken, Natters, Austria; Department II for Internal Medicine, University Hospital of Ulm, Ulm, Germany; Hemato-Oncology Hamburg, Hamburg, Germany; Department of Internal Medicine 4 - Pneumology, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria; Department of Internal Medicine V - Haematology and Oncology, Tirol Kliniken, Medical University Innsbruck, Innsbruck, Austria; Department of Internal Medicine 2, Kardinal Schwarzenberg Hospital, Schwarzach im Pongau, Austria; Department of Thoracic Oncology, LungenClinic, Grosshansdorf, Germany; Airway Research Center North, German Center for Lung Research, Giessen, Germany; Oncology Department, Samson Assuta Ashdod University Hospital, Ashdod, Israel; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel; Department of Medical Oncology, Tumorzentrum, Luzerner Kantonsspital, Spitalstrasse, Luzern, Switzerland; Department of Hematology and Medical Oncology, University Medical Center Mainz, Mainz, Germany; Department of Pulmonology, Unidade Local de Saúde São João, Porto, Portugal; Faculty of Medicine, Universidade do Porto, Porto, Portugal; Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany; 1st Department of Clinical Oncology, Theagenio Cancer Hospital of Thessaloniki, Thessaloniki, Greece; Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands; Medical Oncology Department, Metaxa Cancer Hospital, Piraeus, Greece; Department I of Internal Medicine, Center for Integrated Oncology (CIO), University Hospital of Cologne, Cologne, Germany; European University Cyprus, German Oncology Center, Nicosia, Cyprus; Department of Medical Oncology, St Luke's Clinic, Thessaloniki, Greece; Istituto Oncologico della Svizzera Italiana (IOSI), Ente Ospedaliero Cantonale (EOC), Bellinzona, Switzerland; Department of Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt Universität Berlin, and Berlin Institute of Health, Berlin, Germany; Department of Hematology and Medical Oncology, Pius-Hospital, Department of Internal Medicine-Oncology, University Medicine Oldenburg, Oldenburg, Germany; Department of Pneumology, University Hospital Salzburg, Salzburg, Austria; Department of Medical Oncology, Euromedica - Kianous Stavros Clinic, Thessaloniki, Greece; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria; St Luke’s Hospital, Panorama, Thessaloniki, Greece; Department of Pulmonary Oncology - ULS Santa Maria/Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Oncology Unit, Second Department of Internal Medicine, Attikon University Hospital, Athens, Greece; Department of Respiratory and Pulmonary Diseases, Clinic Penzing, Vienna Healthcare Group, Vienna, Austria; Ludwig Boltzmann Institute for Lung Health, Vienna, Austria; Department of Haematology, Oncology, Gastroenterology and Infectiology, Academic Teaching Hospital Feldkirch, Feldkirch, Austria; Department of Thoracic Oncology, LKI Lungenfachklinik Immenhausen, Immenhausen, Germany; Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel; Sackler Faculty of Medicine, Tel Aviv University, Israel; 7th Respiratory Department, Athens Chest Hospital “Sotiria,” Athens, Greece; Department of Pneumology, Division of Thoracic Oncology and Palliative Care, Lungenklinik Hemer, Hemer, Germany; GenesisCare Maidstone, Kings Hill, West Malling, United Kingdom; UKS Homburg, Homburg, Germany; Oncology, University Hospital St. Pölten, St. Pölten, Lower Austria, Austria; Karl Landsteiner Institute of Nephrology and Hematooncology, Lower Austria, Austria; Hessenklinik Stadtkrankenhaus Korbach, Korbach, Germany; Department of Internal Medicine V, Comprehensive Pneumology Center (CPC-M), Ludwig-Maximilians-Universität Munich, Germany; German Center for Lung Research (DZL), Bavarian Center for Cancer Research (BZKF), Germany; MVZ Oncology and Hematology, Sachsenring, Köln, Germany; Head of Department of Internal Medicine, Head of Laboratory Unit, Executive Medical Director, Krankenhaus St. Vinzenz, Zams, AustriaShow moreShow less
12
days
Identifying Patients With High-Risk Stage I NSCLC Using a Tumor-Informed Plasma ctDNA Assay
Authors
Jamie Feng; Sameena Khan; Thomas K. Waddell; Kazuhiro Yasufuku; Zachary Coyne; Deirdre Kelly; Nicholas Meti; Najib Safieddine; Michael Ko; Andrew Pierre; Shaf Keshavjee; Elliot Wakeam; Laura Donahoe; Marcelo Cypel; Jonathan Yeung; Marc de Perrot; Negar Ahmadi; Sayf Gazala; Carmine Simone; David Parente; Mary R. Rabey; Jennifer H. Law; Janice J.N. Li; Alexandra Salvarrey; Lisa W. Le; Andrew Seto; Michael Cabanero; Ming-Sound Tsao; Christodoulos Pipinikas; Amber Chevalier; Scott V. Bratman; Natasha B. LeighlShow moreShow less
Affiliations
Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Division of Thoracic Surgery, University Health Network (UHN), Toronto, Ontario, Canada; Division of Thoracic Surgery, Michael Garron Hospital, Toronto, Ontario, Canada; Division of Thoracic Surgery, Unity Health Toronto, Toronto, Ontario, Canada; Department of Biostatistics, University Health Network, Toronto, Ontario, Canada; Division of Pathology and Cytogenetics, Laboratory Medicine Program, UHN, Toronto, Ontario, Canada; NeoGenomics Inc., Fort Myers, Florida; Department of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, CanadaShow moreShow less
79
days
Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose Computed Tomography Lung Cancer Screening
Authors
Anna Zanghì; Massimo Moro; Orazio Fortunato; Miriam Segale; Federica Sabia; Paola Suatoni; Roberta E. Ledda; Luigi Rolli; Alfonso Marchianò; Ugo Pastorino; Gabriella Sozzi; Mattia BoeriShow moreShow less
Affiliations
Unit of Epigenomics & Biomarkers of Solid Tumors, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Unit of Thoracic Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Section of Radiology, Unit of Surgical Sciences, Department of Medicine and Surgery (DiMeC), University of Parma, Parma, Italy; Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyShow moreShow less
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review62 days
Median65 days